Compare Amylx Pharmaceuticals Inc (AMLX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Marsh & McLennan Companies, Inc. trades at $189.03 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 34.6× Amylx Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MRSH | |
|---|---|---|
Market Cap | $2.64B | $91.27B |
Sector | Health | Financials |
52-Week High | $24.19 | $211.21 |
52-Week Low | $7.82 | $157.32 |
Enterprise Value | $2.39B | $111.95B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Marsh & McLennan (MRSH) trades at $189.13, down 0.87% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats in Q2 2026, with EPS of $2.96 versus $2.88 expected, and 6% revenue growth highlight operational strength. The company announced the acquisition of Accel to expand its Midwest insurance reach, signaling strategic growth. Valuation metrics show a P/E of 23.35 and robust profitability with a net income margin of 14.24%.
The outlook remains positive with a consensus price target of $202.89, offering potential upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Bank of Nova Scotia increased holdings. The stock presents a solid long-term growth opportunity amid cyclical insurance sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
